drugset / Trial / NCT00638612

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612

Phase 1 Completed 27 enrolled Candel Therapeutics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 1 study is to evaluate the safety and potential efficacy of Gene Mediated Cytotoxic Immunotherapy for pancreatic cancer. The approach uses an adenoviral vector (disabled virus) engineered to express the Herpes thymidine kinase gene (AdV-tk), followed by an antiherpetic prodrug, valacyclovir.

Timeline

Start
2008-08
Primary completion
2013-05
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Valacyclovir Unknown 2 g Oral
Subject aglatimagene besadenovec Unknown 3e+10 unknown Other
Subject aglatimagene besadenovec Unknown 1e+11 unknown Other
Subject aglatimagene besadenovec Unknown 3e+11 unknown Other
Subject aglatimagene besadenovec Unknown 1e+12 unknown Other